Empagliflozin in Heart Failure with a Preserved Ejection Fraction

• Published in: The New England journal of medicine Vol. 385; no. 16; pp. 1451 - 1461
• Main Authors: Anker, Stefan D, Butler, Javed, Filippatos, Gerasimos, Ferreira, João P, Bocchi, Edimar, Böhm, Michael, Brunner–La Rocca, Hans-Peter, Choi, Dong-Ju, Chopra, Vijay, Chuquiure-Valenzuela, Eduardo, Giannetti, Nadia, Gomez-Mesa, Juan Esteban, Janssens, Stefan, Januzzi, James L, Gonzalez-Juanatey, Jose R, Merkely, Bela, Nicholls, Stephen J, Perrone, Sergio V, Piña, Ileana L, Ponikowski, Piotr, Senni, Michele, Sim, David, Spinar, Jindrich, Squire, Iain, Taddei, Stefano, Tsutsui, Hiroyuki, Verma, Subodh, Vinereanu, Dragos, Zhang, Jian, Carson, Peter, Lam, Carolyn Su Ping, Marx, Nikolaus, Zeller, Cordula, Sattar, Naveed, Jamal, Waheed, Schnaidt, Sven, Schnee, Janet M, Brueckmann, Martina, Pocock, Stuart J, Zannad, Faiez, Packer, Milton
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 14.10.2021
• Subjects: Adult; Antidiabetics; Benzhydryl Compounds - administration & dosage; Benzhydryl Compounds - adverse effects; Cardiology; Cardiology and cardiovascular system; Cardiology General; Cardiovascular diseases; Cardiovascular Diseases - mortality; Cardiovascular Diseases - prevention & control; Chronic Disease; Congestive heart failure; Diabetes; Diabetes mellitus; Double-Blind Method; Ejection fraction; Female; Glucosides - administration & dosage; Glucosides - adverse effects; Heart Failure; Heart Failure - drug therapy; Heart Failure - physiopathology; Hospitalization - statistics & numerical data; Human health and pathology; Humans; Hypotension; Life Sciences; Male; Patient safety; Placebos; Sodium-glucose cotransporter; Sodium-Glucose Transporter 2 Inhibitors - administration & dosage; Sodium-Glucose Transporter 2 Inhibitors - adverse effects; Statistical analysis; Stroke Volume; Urinary tract

In a randomized trial, 5988 patients with heart failure with preserved ejection fraction were assigned to receive either empagliflozin or placebo in addition to usual therapy. At a median of 26 months, the empagliflozin group had a lower incidence of cardiovascular death or hospitalization for heart...